Actively Recruiting

Age: 6Years - 17Years
All Genders
NCT06287268

Revolade Tablets Specified Drug-use Survey

Led by Novartis Pharmaceuticals · Updated on 2026-02-19

10

Participants Needed

17

Research Sites

223 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).

CONDITIONS

Official Title

Revolade Tablets Specified Drug-use Survey

Who Can Participate

Age: 6Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient's legal guardian has provided written consent to participate in this survey
  • Patients aged 6 years and older but younger than 18 years at the start of eltrombopag treatment
  • Pediatric patients with aplastic anemia receiving eltrombopag for the first time combined with ATG after approval for this use
Not Eligible

You will not qualify if you...

  • Patients who have received ATG treatment without using eltrombopag
  • Patients diagnosed with congenital aplastic anemia
  • Patients suspected or confirmed to have myelodysplastic syndrome at the start of eltrombopag treatment
  • Patients who have previously received any drug containing eltrombopag (including experimental treatments)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Novartis Investigative Site

Nagoya, Aichi-ken, Japan, 453-8511

Actively Recruiting

2

Novartis Investigative Site

Nagoya, Aichi-ken, Japan, 4668560

Actively Recruiting

3

Novartis Investigative Site

Toyoake, Aichi-ken, Japan, 4701192

Actively Recruiting

4

Novartis Investigative Site

Chiba, Chiba, Japan, 260 8677

Actively Recruiting

5

Novartis Investigative Site

Amagasaki, Hyōgo, Japan, 660 8550

Actively Recruiting

6

Novartis Investigative Site

Kobe, Hyōgo, Japan, 6500047

Actively Recruiting

7

Novartis Investigative Site

Matsumoto, Nagano, Japan, 3908621

Actively Recruiting

8

Novartis Investigative Site

Shimajiri-Gun, Okinawa, Japan, 901-1303

Actively Recruiting

9

Novartis Investigative Site

Izumi, Osaka, Japan, 5941101

Actively Recruiting

10

Novartis Investigative Site

Osaka, Osaka, Japan, 5340021

Actively Recruiting

11

Novartis Investigative Site

Sakai, Osaka, Japan, 590-0197

Actively Recruiting

12

Novartis Investigative Site

Saitama, Saitama, Japan, 3308777

Actively Recruiting

13

Novartis Investigative Site

Ohtsu, Shiga, Japan, 5202192

Actively Recruiting

14

Novartis Investigative Site

Chuo Ku, Tokyo, Japan, 1048560

Actively Recruiting

15

Novartis Investigative Site

Ōta-ku, Tokyo, Japan, 143 8541

Actively Recruiting

16

Novartis Investigative Site

Setagaya-ku, Tokyo, Japan, 1578535

Actively Recruiting

17

Novartis Investigative Site

Wakayama, Wakayama, Japan, 641-8510

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Revolade Tablets Specified Drug-use Survey | DecenTrialz